Back to Search
Start Over
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.
- Source :
-
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2023 Jun 16; Vol. 17 (6), pp. e0011425. Date of Electronic Publication: 2023 Jun 16 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Malaria is caused by parasite of the genus Plasmodium and is still one of the most important infectious diseases in the world. Several biological characteristics of Plasmodium vivax contribute to the resilience of this species, including early gametocyte production, both of which lead to efficient malaria transmission to mosquitoes. This study evaluated the impact of currently used drugs on the transmission of P. vivax. Participants received one of the following treatments for malaria: i) chloroquine [10 mg/kg on day 1 and 7.5 mg/kg on day 2 and 3] co-administered with Primaquine [0.5 mg/kg/day for 7 days]; ii) Chloroquine [10 mg/kg on day 1 and 7.5 mg/kg on day 2 and 3] co-administered with one-dose of Tafenoquine [300 mg on day 1]; and iii) Artesunate and Mefloquine [100 mg and 200 mg on day 1, 2 and 3] co-administered with Primaquine [0.5 mg/kg/day for 14 days]. Patient blood was collected before treatment and 4 h, 24 h, 48 h and 72 h after treatment. The blood was used to perform a direct membrane feeding assay (DMFA) using Anopheles darlingi mosquitoes. The results showed 100% inhibition of the mosquito infection after 4 h using ASMQ+PQ, after 24 h for the combination of CQ+PQ and 48 h using CQ+TQ. The density of gametocytes declined over time in all treatment groups, although the decline was more rapid in the ASMQ+PQ group. In conclusion, it was possible to demonstrate the transmission-blocking efficacy of the malaria vivax treatment and that ASMQ+PQ acts faster than the two other treatments.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Subjects :
- Animals
Humans
Primaquine pharmacology
Primaquine therapeutic use
Chloroquine pharmacology
Chloroquine therapeutic use
Plasmodium vivax
Antimalarials pharmacology
Antimalarials therapeutic use
Malaria, Vivax drug therapy
Malaria, Vivax parasitology
Anopheles parasitology
Malaria drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1935-2735
- Volume :
- 17
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- PLoS neglected tropical diseases
- Publication Type :
- Academic Journal
- Accession number :
- 37327209
- Full Text :
- https://doi.org/10.1371/journal.pntd.0011425